Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (Q33387733)

26 July 2017

title

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

phase I clinical trial

0 references

0 references

phase II clinical trial

0 references

0 references

1 reference

Federica Cavallo

9

0 references

Alessandra Larocca

Alessandra Larocca

2

0 references

Gianluca Gaidano

14

Gianluca Gaidano

2 references

26 July 2017

ORCID Public Data File 2021

Kenneth C. Anderson

16

Kenneth Anderson

1 reference

26 July 2017

18

Paul Richardson

1 reference

26 July 2017

1

Antonio Palumbo

1 reference

26 July 2017

Constantine S Mitsiades

15

Constantine Mitsiades

1 reference

26 July 2017

5

Francesca Gay

1 reference

26 July 2017

10

Sara Bringhen

1 reference

26 July 2017

13

Massimo Iacobelli

1 reference

26 July 2017

17

Mario Boccadoro

1 reference

26 July 2017

8

Valeria Magarotto

1 reference

26 July 2017

Mariella Genuardi

3

1 reference

26 July 2017

Katarzyna Kotwica

4

1 reference

26 July 2017

Davide Rossi

6

1 reference

26 July 2017

Giulia Benevolo

7

1 reference

26 July 2017

Cecilia Rus

11

1 reference

26 July 2017

Luciano Masini

12

1 reference

26 July 2017

Italian Multiple Myeloma Network GIMEMA

19

1 reference

26 July 2017

publication date

6 January 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

95

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1144-1149

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

International uniform response criteria for multiple myeloma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2895039

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20053869

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20053869

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20053869

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2009.017913

1 reference

26 July 2017

1 reference

26 July 2017

1 reference